

FGF-basic

Catalog # PVGS1686

Product Information

Primary Accession Species	<u>XP_035600424.1</u> Salmon
Sequence	Full length
Purity	≥ 95% as analyzed by SDS-PAGE
Endotoxin Level Biological Activity	$EC_{50 50}$, the calculated specific activity is approximately > 1.0 × 10 ⁶ IU/mg. It is recommended to experimentally determine the optimal concentration for each specific application by performing a dose response assay.
Expression System	E. coli
Theoretical Molecular Weight	17.1 kDa
Formulation	Lyophilized from a 0.2 Im filtered solution in 7.8 mM Na ₂ HPO ₄ , 1.5 mM
Reconstitution	KH ₂ PO ₄ , 2.7 mM KCl, 500 mM NaCl. Before opening, centrifuge the vial briefly to bring the contents to the bottom. Reconstitute the lyophilized powder in PBS up to 100 [g/ml.
Storage & Stability	Upon receiving, the lyophilized product remains stable for up to 6 months at lower than -70 °C. Upon reconstitution, the product is stable for up to 1 week at 4 °C or up to 3 months at -20 °C. Avoid repeated freeze-thaw cycles by making single-use aliquots before the solution is storage at -20 °C.

Additional Information

pleiotropic cytokine and one of the prototypic members of the heparin-binding FGF family. Like other FGF family members, FGF-basic ha β trefoil structure. In vivo, FGF-basic is produced by a variety of cells, including cardiomyocytes, fibroblasts, and vascular cells. FGF-basic regula a variety of processes including cell proliferation, differentiation, survival, adhesion, motility, apoptosis, limb formation and wound healing. FGF-basic can be tumorigenic due to its role in angiogenesis and blood vessel remodeling. The angiogenic effects of FGF-basic can produce beneficial cardioprotection during acute heart injury.
--

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.